| SNGX Stock | | | USD 3.28 0.15 4.79% |
SVP
Dr. Oreola Donini, Ph.D., is Senior Vice President, Chief Scientific Officer of Soligenix, Inc. was with our company since August 15, 2013 and is currently our Chief Scientific Officer and Senior Vice President, a position she has held since December 5, 2014. She served as our Vice President of Preclinical Research and Development from August 15, 2013 until December 4, 2014. Dr. Donini is a coinventor and leader of the Companys SGX94 innate defense regulator technology, developed by Inimex and subsequently acquired by the Company. She was responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation andor chemotherapy treatment. These preclinical studies resulted in a successful Phase 1 clinical study and clearance of Phase 2 protocols for oral mucositis in head and neck cancer and acute bacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of Research and Development, Dr. Donini led the preclinical testing of a novel Nterminal domain inhibitor of the androgen receptor for the treatment of prostate cancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase inhibitors for the treatment of cancer since 2014.
| Age | 53 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 29 Emmons Drive, Princeton, NJ, United States, 08540 |
| Phone | 609 538 8200 |
| Web | https://www.soligenix.com |
Donini received her PhD from Queen’s University in Kinston, Ontario, Canada and completed her postdoctoral work at the University of California, San Francisco. Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in infectious disease, cancer and cancer supportive care.
Soligenix Management Efficiency
The company has return on total asset
(ROA) of
(0.4514) % which means that it has lost $0.4514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.398) %, meaning that it created substantial loss on money invested by shareholders. Soligenix's management efficiency ratios could be used to measure how well Soligenix manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.59 in 2025.
Return On Capital Employed is likely to rise to -1.81 in 2025. At this time, Soligenix's
Other Current Assets are fairly stable compared to the past year.
Other Assets is likely to rise to about 207.7
K in 2025, whereas
Total Assets are likely to drop slightly above 10
M in 2025.
Soligenix currently holds 3.49
M in liabilities with Debt to Equity
(D/E) ratio of 2.44, implying the company greatly
relies on financing operations through barrowing. Soligenix has a current ratio of 2.31, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Soligenix's use of debt, we should always consider it together with its cash and equity.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. Soligenix (SNGX) is traded on NASDAQ Exchange in USA. It is located in 29 Emmons Drive, Princeton, NJ, United States, 08540 and employs 13 people. Soligenix is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Soligenix Leadership Team
Elected by the shareholders, the Soligenix's board of directors comprises two types of representatives: Soligenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Soligenix. The board's role is to monitor Soligenix's management team and ensure that shareholders' interests are well served. Soligenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Soligenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
Soligenix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Soligenix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Soligenix Stock Analysis
When running Soligenix's price analysis, check to
measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to
predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.